Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Receivables (2024 - 2025)

PharmaCyte Biotech (PMCB) has disclosed Receivables for 5 consecutive years, with $3.4 million as the latest value for Q1 2025.

  • Quarterly Receivables changed N/A to $3.4 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Jan 2025, changed N/A year-over-year, with the annual reading at $2.8 million for FY2024, N/A changed from the prior year.
  • Receivables for Q1 2025 was $3.4 million at PharmaCyte Biotech, up from $2.8 million in the prior quarter.
  • The five-year high for Receivables was $3.4 million in Q1 2025, with the low at $2.8 million in Q2 2024.